{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:33:14Z","timestamp":1794864794513,"version":"4.9.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Treatment options for patients with non\u2013small cell lung cancer (NSCLC) who have progressed on anti\u2013PD-(L)1 treatment are lacking. In preclinical models, blockade of the inhibitory immune receptor T-cell immunoglobulin and mucin-domain containing protein 3 (TIM-3) is associated with an antitumor response. AMBER (NCT02817633) part 2B assessed the safety and efficacy of cobolimab, an anti\u2013TIM-3 humanized monoclonal antibody, plus PD-1 inhibitor dostarlimab in patients with locally advanced or metastatic NSCLC who had progressed on anti\u2013PD-(L)1 treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Adult patients with anti\u2013PD-(L)-1 treated locally advanced or metastatic NSCLC were included. Patients received cobolimab 100, 300, or 900 mg and dostarlimab 500 mg every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, patient withdrawal, investigator\u2019s decision, or death. Endpoints included overall response rate, disease control rate, and safety. Post hoc biomarker assessments of pretreatment tumor biopsies were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 85 patients were enrolled and 84 received treatment. Treatment-emergent and treatment-related adverse events occurred in 98.8% and 52.4% of patients, respectively; no treatment-related deaths occurred. Across all three cobolimab doses, overall response rate was 8.3% (95% confidence interval, 3.4\u201316.4) and disease control rate was 21.4% (95% confidence interval, 13.2\u201331.7); both were highest in the 300 mg cohort (n = 41; 9.8% and 22.0%). Pretreatment TIM-3 expression was significantly greater in patients with partial or stable responses versus progressive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cobolimab plus dostarlimab showed preliminary efficacy and tolerability in a subset of patients with locally advanced\/metastatic NSCLC.<\/jats:p>\n                    <jats:p>See related article by Davar et al., p. 3433<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-25-0806","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:29:47Z","timestamp":1750757387000},"page":"3443-3451","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non\u2013Small Cell Lung Cancer: AMBER Part 2B"],"prefix":"10.1158","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"first","affiliation":[{"name":"1Department of Medicine - Hematology\/Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-7030","authenticated-orcid":false,"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[{"name":"2Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-6824","authenticated-orcid":false,"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, University of Iowa, Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7735-8010","authenticated-orcid":false,"given":"Carlos","family":"Becerra","sequence":"additional","affiliation":[{"name":"4The US Oncology Network, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3159","authenticated-orcid":false,"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Hackensack Meridian Health, Hackensack, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"6Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-9970","authenticated-orcid":false,"given":"Brian","family":"Di Pace","sequence":"additional","affiliation":[{"name":"7GSK, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3294-4670","authenticated-orcid":false,"given":"Tianli","family":"Wang","sequence":"additional","affiliation":[{"name":"8GSK, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8977-813X","authenticated-orcid":false,"given":"Hailei","family":"Zhang","sequence":"additional","affiliation":[{"name":"8GSK, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6330-398X","authenticated-orcid":false,"given":"Srimoyee","family":"Ghosh","sequence":"additional","affiliation":[{"name":"8GSK, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1585-6007","authenticated-orcid":false,"given":"Niranjan","family":"Yanamandra","sequence":"additional","affiliation":[{"name":"7GSK, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6029-4002","authenticated-orcid":false,"given":"Theo","family":"Borgovan","sequence":"additional","affiliation":[{"name":"8GSK, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8955-3378","authenticated-orcid":false,"given":"Shyam","family":"Srivats","sequence":"additional","affiliation":[{"name":"7GSK, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8620-0488","authenticated-orcid":false,"given":"Angela","family":"Waszak","sequence":"additional","affiliation":[{"name":"8GSK, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-0877","authenticated-orcid":false,"given":"Arindam","family":"Dhar","sequence":"additional","affiliation":[{"name":"7GSK, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-036X","authenticated-orcid":false,"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"9Yale University, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2025081403083587800_bib1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"2025081403083587800_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2025081403083587800_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"2025081403083587800_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"key":"2025081403083587800_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD\u20131 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2025081403083587800_bib6","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J Immunol"},{"key":"2025081403083587800_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2005","journal-title":"Int Immunol"},{"key":"2025081403083587800_bib8","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib9","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"2025081403083587800_bib10","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025081403083587800_bib12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025081403083587800_bib13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib14","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025081403083587800_bib17","doi-asserted-by":"crossref","first-page":"6984948","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies","volume":"2018","author":"Sui","year":"2018","journal-title":"J Immunol Res"},{"key":"2025081403083587800_bib18","volume-title":"Cancer facts & figures 2023","author":"American Cancer Society","year":"2023"},{"key":"2025081403083587800_bib19","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.3390\/cancers15184547","article-title":"Update in Immunotherapy for advanced non-small cell lung cancer: optimizing treatment sequencing and identifying the best choices","volume":"15","author":"Roque","year":"2023","journal-title":"Cancers"},{"key":"2025081403083587800_bib20","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1038\/s41467-023-42900-4","article-title":"Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"2025081403083587800_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"key":"2025081403083587800_bib22","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025081403083587800_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"2025081403083587800_bib24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"de Mingo Pulido","year":"2021","journal-title":"Immunity"},{"key":"2025081403083587800_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"key":"2025081403083587800_bib26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.21037\/jtd-23-227","article-title":"Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study","volume":"15","author":"Zhang","year":"2023","journal-title":"J Thorac Dis"},{"key":"2025081403083587800_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1309\/AJCP9Q6OVLVSHTMY","article-title":"Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC","volume":"137","author":"Zhuang","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2025081403083587800_bib28","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non\u2013small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025081403083587800_bib29","doi-asserted-by":"crossref","first-page":"e000294","DOI":"10.1136\/jitc-2019-000294","article-title":"Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer","volume":"8","author":"Sun","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025081403083587800_bib30","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"2025081403083587800_bib31","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0959-8049(16)32903-3","article-title":"Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody","volume":"69","author":"Murtaza","year":"2016","journal-title":"Eur J Cancer"},{"issue":"Suppl","key":"2025081403083587800_bib32","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","article-title":"Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)","volume":"40","author":"Falchook","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025081403083587800_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025081403083587800_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2025081403083587800_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"Suppl","key":"2025081403083587800_bib36","doi-asserted-by":"crossref","first-page":"Abstract 9513","DOI":"10.1200\/JCO.2022.40.16_suppl.9513","article-title":"AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced\/metastatic melanoma","volume":"40","author":"Ribas","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025081403083587800_bib37","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025081403083587800_bib38","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025081403083587800_bib39","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"key":"2025081403083587800_bib40","first-page":"874","article-title":"The antitumor efficacy of TIM-3 blockade in a murine model of sarcoma","volume":"6","author":"McEachern","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"Suppl","key":"2025081403083587800_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.2023.41.4_suppl.580","article-title":"Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma","volume":"41","author":"Acoba","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025081403083587800_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunological Rev"},{"key":"2025081403083587800_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"2025081403083587800_bib44","volume-title":"Therapeautic targeting of intratumoral dendritic cells","author":"Ruffell","year":"2022"},{"issue":"Suppl 1","key":"2025081403083587800_bib45","first-page":"A678","article-title":"596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy","volume":"11","author":"Davar","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-0806\/3625165\/ccr-25-0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/31\/16\/3443\/3639368\/ccr-25-0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/31\/16\/3443\/3639368\/ccr-25-0806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T07:08:49Z","timestamp":1755155329000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/31\/16\/3443\/763986\/Combined-Targeting-of-PD-1-and-TIM-3-in-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":45,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-0806","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.7981497","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.29908659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29908680","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}